Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 13/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29452903 | 1.00 | GPR52 (1.00) | GPR52TP53HPGDKDM4ELMNA | |
| SCHEMBL3218938 | 0.94 | GPR52 (0.88) | GPR52HPGDALOX15 | |
| SCHEMBL3204292 | 0.94 | GPR52 (0.88) | GPR52TP53HPGDKDM4ELMNA | |
| SCHEMBL3210142 | 0.93 | GPR52 (0.87) | GPR52TP53HPGDLMNAMAPT | |
| SCHEMBL3204403 | 0.93 | GPR52 (0.86) | GPR52TP53LMNAMAPTSNCA | |
| SCHEMBL3213566 | 0.92 | GPR52 (0.85) | GPR52TP53SNCA | |
| SCHEMBL3197888 | 0.90 | GPR52 (0.81) | GPR52MRGPRX4 | |
| SCHEMBL3210761 | 0.90 | GPR52 (0.81) | GPR52TP53HPGDKDM4ELMNA | |
| SCHEMBL3220886 | 0.90 | GPR52 (0.81) | GPR52LMNASNCA | |
| SCHEMBL13489581 | 0.90 | GPR52 (0.81) | GPR52TP53HPGDKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055016-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| EP-4401833-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20240376070-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2024-11-14 | — | — | US | disclosed |
| EP-4117784-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-20240254101-A1 | GPR52 MODULATOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| CN-117999258-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230348416-A1 | GPR52 MODULATOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| CN-116507622-A | GPR52 modulator compounds | 赫帕雷斯治疗有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4204408-A1 | GPR52 MODULATOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023041909-A1 | GPR52 MODULATOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-03-23 | — | — | WO | disclosed |
| EP-4117784-A1 | GPR52 MODULATOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-01-18 | — | — | EP | disclosed |
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-115515681-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-114650992-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2021181122-A1 | GPR52 MODULATOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | WO | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR4 | GPR52 1/4885TP53 3995/4885HPGD 2466/4885 |
| US-20230348416-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, FFAR2 | GPR52 1/4885TP53 4047/4885HPGD 2627/4885 |
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885TP53 3403/4885HPGD 2979/4885 |
| US-20240376070-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR27 | GPR52 1/4885TP53 4089/4885HPGD 3192/4885 |
| US-20240254101-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR4 | GPR52 1/4885TP53 3830/4885HPGD 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.